CAMBRIDGE, MA, January 24, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking down barriers in gene therapy and neurology, has signed two newly hired employees. Restricted Stock Units as an incentive for such employees to join Voyager. The Incentive Award was approved by the Compensation Committee of Voyager’s Board of Directors pursuant to Nasdaq Stock Exchange Listing Rule 5635(c)(4). The option grants to each employee are expected to become effective on January 23, 2023 and the restricted stock unit grants to each employee are expected to be effective on April 1, 2023.
A stock option grant to one employee enables the purchase of 100,000 shares of Voyager common stock, and a restricted stock unit grant to that employee is equivalent to 50,000 shares of Voyager common stock. Stock option grants to other employees provide for the purchase of a total of 50,000 shares of Voyager common stock, and restricted stock unit grants to that employee represent his 25,000 shares of Voyager common stock. To do. Each stock option has a term of 10 years and an exercise price of $9.16 per his share. This corresponds to the closing price of Voyager common stock on his January 23, 2023, the effective date of the grant. Each stock option vests over a period of four years. 25% of shares eligible for stock options will vest one year after the effective date of grant and 75% of shares eligible for stock options will vest in 36 equal monthly installments one year after the effective date of grant rights are confirmed. Effective date of grant. Each Restricted Stock Unit award vests annually in equal installments over a three-year period beginning on the first anniversary of the effective date of the grant. Vesting of each employee’s stock award is contingent upon that employee’s continued employment with Voyager. Each Stock Award is also subject to the terms of the Award Agreement.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking down barriers in gene therapy and neurology. The potential in both areas is limited by delivery challenges. Voyager leverages its cutting-edge capsid discovery expertise and deep neuropharmacology capabilities to address these limitations. Voyager’s TRACER™ AAV capsid discovery platform generates novel capsids with high targeted delivery and blood-brain barrier permeability at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors . The platform powers partnerships with Pfizer, Novartis, Neurocline and his Biosciences, as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes 100% owned joint preclinical programs in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia, each with valid targets and biomarkers, allowing a rapid route to potential biological proof. For more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark and TRACER™ is a trademark of Voyager Therapeutics, Inc.